Given that FBXW7 missense (but not truncating) mutations are common in normal endometrial glands (Moore et al, 2020) and that its substrates appear to vary by tissue (Davis et al, 2014a), addressing these is critical if FBXW7 is to be a target for endometrial cancer prevention and therapy. This evidence concerns the gene FBXW7 and endometrial cancer.